109944-15-2
中文名稱
幾夫堿
英文名稱
KIFUNENSINE
CAS
109944-15-2
分子式
C8H12N2O6
分子量
232.19
MOL 文件
109944-15-2.mol
更新日期
2026/03/24 13:52:10
109944-15-2 結構式
基本信息
中文別名
幾夫堿 英文別名
FR 900494KIFUNENSINE
Kifunensine min. 99%
[5R-(5α,6β,7α,8α,8aα)]-
KIFUNENSINE, KITASATOSPORIA KIFUNENSE
Hexahydro-6R,7S,8aS-trihydroxy-5R-(hydroxymethyl)-imidazo[1,2-a] pyridine-2,3-dione
(5R,6R,7S,8R,8AS)-6,7,8-trihydroxy-5-(hydroxymethyl)hexahydroimidazo[1,2-a]pyridine-2,3-dione
(5R,6R,7S,8R,8aS)-Hexahydro-6,7,8-trihydroxy-5-(hydroxymethyl)-imidazo[1,2-a]pyridine-2,3-dione
FR 900494, Hexahydro-6R,7S,8aS-trihydroxy-5R-(hydroxymethyl)-imidazo[1,2-a] pyridine-2,3-dione
Imidazo1,2-apyridine-2,3-dione, hexahydro-6,7,8-trihydroxy-5-(hydroxymethyl)-, (5R,6R,7S,8R,8aS)-
物理化學性質
熔點>280°C
密度1.85±0.1 g/cm3(Predicted)
儲存條件−20°C
溶解度二次蒸餾水中的溶解度：50MM
酸度系數(pKa)9.61±0.70(Predicted)
形態(tài)白色固體
顏色白色
生物來源synthetic (organic)
水溶解性Soluble to 5 mM in water with sonication
穩(wěn)定性干燥并儲存在-20°C
InChI1S/C8H12N2O6/c11-1-2-3(12)4(13)5(14)6-9-7(15)8(16)10(2)6/h2-6,11-14H,1H2,(H,9,15)/t2-,3-,4+,5+,6+/m1/s1
InChIKeyOIURYJWYVIAOCW-PQMKYFCFSA-N
SMILESN21[C@H](NC(=O)C2=O)[C@H]([C@H]([C@@H]([C@H]1CO)O)O)O
幾夫堿價格(試劑級)
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-19332R | 幾夫堿 Kifunensine (Standard) | 109944-15-2 | 1 mg | 2500元 |
| 2026/06/05 | HY-19332R | 幾夫堿 Kifunensine (Standard) | 109944-15-2 | 5 mg | 6000元 |
| 2026/06/05 | HY-19332 | 幾夫堿 Kifunensine | 109944-15-2 | 1 mg | 1364元 |
常見問題列表
生物活性
Kifunensine 是可從放線菌中分離得到的 I 類 α-mannosidases 有效選擇性抑制劑，可阻斷 α-mannosidases I 修剪糖蛋白上的甘露糖殘基。Kifunensine 可抑制內質網相關蛋白降解途徑。體外研究
Kifunensine, an alkaloid from actinomycete Kitasatosporia kifunense 9482, is the most efficient nhibitor of a-mannosidase I, blocking N-glycan synthesis at an8GlcNAc 2 (Man8) or Man9GlcNAc 2 (Man9) stage.
RT-PCR.
| Cell Line: | Hybridoma cells expressing a human IgG1 monoclonal Antibody [3] . |
| Concentration: | 2 μg/mL. |
| Incubation Time: | 4 days. |
| Result: |
Significantly reduced the lentil lectin binding.
Kifunensine is the most effective among the inhibitors tested in producing antibodies containing oligomannose residues without fucose. |
體內研究
| Animal Model: | BALB/c mice. |
| Dosage: | 5 mg/kg. |
| Administration: | IV via tail vein. |
| Result: | There was no significant difference in the serum levels of anti-TEM B mAb generated from cells treated with or without kifunensine in the 7-day period. |